Related Experiment Video
Updated: Jun 4, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Changes in serum cholesterol loading capacity are linked to coronary atherosclerosis progression in rheumatoid
George Athanasios Karpouzas1,2, Bianca Papotti3, Sarah R Ormseth4
1Internal Medicine- Rheumatology, The Lundquist Institute, Torrance, California, USA gkarpouzas@lundquist.org.
Insights
Changes in cholesterol loading capacity (CLC) in rheumatoid arthritis (RA) patients predict atherosclerosis progression. RA therapies like biologics and statins may favorably impact this relationship, unlike prednisone.
Area of Science:
- Cardiovascular Science
- Rheumatology
- Immunology
Background:
- Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, partly due to cholesterol loading on macrophages leading to foam cell formation.
- The impact of evolving cholesterol loading capacity (CLC) and RA treatments on coronary plaque progression in RA patients remains unclear.
Purpose of the Study:
- To investigate the association between longitudinal changes in CLC and the progression of coronary atherosclerosis in patients with RA.
- To explore the influence of RA therapies on the relationship between CLC changes and atherosclerosis.
Main Methods:
- A prospective observational cohort study involving 100 RA patients without baseline cardiovascular disease.
- Coronary CT angiography assessed atherosclerosis (plaque types, CAC score) at baseline and after ~7 years. Serum CLC was measured using a fluorometric assay on monocyte-derived macrophages.
- Progression defined by plaque changes, increased CAC score, or development of extensive/obstructive disease.
Main Results:
- Increased CLC change was significantly associated with a higher likelihood of progression in non-calcified plaques (OR 2.55), fully calcified plaques (OR 3.10), and coronary artery calcium (CAC) score (OR 1.80).
- Higher CLC change also predicted new extensive or obstructive coronary artery disease (OR 2.43).
- Prednisone use showed an unfavorable interaction, while biologics and statins demonstrated favorable interactions with CLC change regarding atherosclerosis progression (p≤0.048).
Conclusions:
- Longitudinal changes in cholesterol loading capacity are a significant predictor of atherosclerosis progression in RA patients.
- This association is dose-dependent and includes the development of lipid-rich non-calcified plaques and extensive or obstructive coronary artery disease, which pose the highest cardiovascular risk.
- RA therapies differentially modulate the link between CLC dynamics and cardiovascular disease progression.
Objective:
Excess cholesterol loading on arterial macrophages is linked to foam cell formation, atherosclerosis and cardiovascular risk in rheumatoid arthritis (RA). However, the effect of changes in cholesterol loading on coronary plaque trajectory and the impact of RA therapies on this relationship are unknown. We investigated the association between variations in cholesterol loading capacity (CLC) over time and atherosclerosis progression.
Methods:
In a prospective observational cohort study, coronary CT angiography evaluated atherosclerosis (non-calcified, partially calcified or fully calcified plaques and coronary artery calcium (CAC) score) in 100 patients with RA without cardiovascular disease at baseline and 6.9±0.4 years later. The presence of ≥5 plaques and lesions rendering >50% stenosis was considered an extensive and obstructive disease, respectively. Serum CLC was measured on human THP-1 monocyte-derived macrophages with a fluorometric assay.
Results:
Mean CLC change (follow-up CLC-baseline CLC) was 1.54 (SD 3.69) μg cholesterol/mg protein. In models adjusting for atherosclerotic cardiovascular disease risk score, baseline plaque and other relevant covariates, CLC change (per SD unit increase) is associated with a higher likelihood of progression of non-calcified (OR 2.55, 95% CI 1.22 to 5.35), fully calcified plaque (OR 3.10, 95% CI 1.67 to 5.76), CAC (OR 1.80, 95% CI 1.18 to 2.74) and new extensive or obstructive disease (OR 2.43, 95% CI 1.11 to 5.34). Exposure to prednisone unfavourably influenced, while biologics and statins favourably affected the relationship between CLC change and atherosclerosis progression (all p-for-interactions ≤0.048).
Conclusion:
CLC change is associated with atherosclerosis progression in a dose-dependent manner, including lipid-rich non-calcified plaques and extensive or obstructive disease that yield the greatest cardiovascular risk.
More Related Videos
09:41Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Related Concept Videos
Inflammation
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Lipids: Dietary Sources and Requirements